Immunomodulator effect of picroliv and its potential in treatment against resistant Plasmodium yoelii (MDR) infection in mice.
OBJECTIVE
The present study was envisaged to evaluate potential of combination therapy comprising of immunomodulator picroliv and antimalarial chloroquine against drug resistant Plasmodium yoelii (P. yoelii) infection in BALB/c mice.


METHODS
The immunomodulatory potential of picroliv was established by immunizing animals with model antigen along with picroliv. Immune response was assessed using T-cell proliferation assay and also by determining the antibody isotype-profile induced in the immunized mice. In the next set of experiment, prophylactic potential of picroliv to strengthen antimalarial properties of chloroquine against P. yoelii (MDR) infection in BALB/c mice was assessed.


RESULTS
T-cell proliferation as well as antibody production study reveals that picroliv helps in evoking strong immuno-potentiating response against model antigen in the immunized mice. Co-administration of picroliv enhances efficacy of CHQ against experimental murine malaria.


CONCLUSIONS
The activation of host immune system can increase the efficacy of chloroquine for suppression of drug resistant malaria infection in BALB/c mice.
Department of Biochemistry, J. N. Medical College, Aligarh Muslim University, Aligarh, India.
Varun
V
Dwivedi
Arif
A
Khan
Azevedo
A
Vasco
Nishat
N
Fatima
Vishal Kumar
VK
Soni
Anil
A
Dangi
Shailja
S
Misra-Bhattacharya
Mohammad
M
Owais
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen / Q000378:metabolism; D002738:Chloroquine / Q000494:pharmacology*; D002934:Cinnamates / Q000494:pharmacology*; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D005260:Female; D006027:Glycosides / Q000494:pharmacology*; D007074:Immunoglobulin G / Q000097:blood; D007155:Immunologic Factors / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008288:Malaria / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology; D010967:Plasmodium yoelii / Q000187:drug effects* / Q000276:immunology; D017382:Reactive Oxygen Species / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013997:Time Factors; D015854:Up-Regulation; D014641:Vanillic Acid / Q000494:pharmacology*
D000962:Antimalarials; D018122:B7-1 Antigen; D051940:B7-2 Antigen; C497965:Cd86 protein, mouse; D002934:Cinnamates; D006027:Glycosides; D007074:Immunoglobulin G; D007155:Immunologic Factors; D017382:Reactive Oxygen Species; C057463:kutkin; D002738:Chloroquine; D010047:Ovalbumin; D014641:Vanillic Acid